source
- Vanda halts Novartis-originated social anxiety drug after Phase 3 missVanda Pharmaceuticals announced it is suspending development of VQW-765, a social anxiety disorder candidate licensed from Novartis, after the drug failed to demonstrate a statistically significant…
- OrbiMed raises $3 billion, its biggest Asian fund yet, to boost biotech investments worldwideOrbiMed announced it has closed a $3 billion fundraising round, the largest ever for its Asia‑focused vehicle. The capital will be used to make new growth‑equity and venture investments in biotech…